CGA and neoplasm: In terms of circulating biomarkers, baseline CgA has been linked to tumor burden and poorer PRRT outcomes - for example, one analysis identified elevated CgA as an adverse prognostic factor (combined with tumor volume, HR ~2.7 for 5-year OS) and determined a high cutoff (~1250 μg/L) that predicted significantly lower survival​ 46.